Nektar Therapeutics (NKTR) vs Omeros (OMER)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Omeros (OMER) has outperformed Nektar Therapeutics (NKTR) over the past year, gaining 322.3% versus a loss of 30.6%. Over five years, OMER leads with a +142.6% price change compared with -84.5% for NKTR. Nektar Therapeutics is the larger company by market cap ($1.38 billion vs $1.36 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NKTR | OMER |
|---|---|---|
| Share price | $40.37 | $18.80 |
| Market cap | $1.38B | $1.36B |
| 1-day change | +0.27% | +0.27% |
| YTD return | -4.78% | +9.14% |
| 1-year return | -30.59% | +322.30% |
| 5-year return | -84.49% | +142.56% |
| P/E ratio (TTM) | — | 15.41 |
| Forward P/E | — | 15.28 |
| EPS (TTM) | $-18.96 | $1.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $109.00 | $21.24 |
| 52-week low | $33.40 | $4.06 |
| Distance from 52-week high | -62.96% | -11.49% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +250.26% | +46.28% |
| Average volume | 1.06M | 1.74M |
| Shares outstanding | 34.14M | 72.39M |
| Employees | 63 | 175 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OMER has outperformed NKTR by 352.9 percentage points over the past year.
About Nektar Therapeutics
NKTR stock →Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 63 employees
About Omeros
OMER stock →Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 175 employees
NKTR vs OMER FAQ
Which is bigger, Nektar Therapeutics or Omeros?
Nektar Therapeutics (NKTR) is larger, with a market capitalization of $1.38B compared with $1.36B for Omeros (OMER).
Which stock has performed better over the past year, NKTR or OMER?
OMER returned +322.30% over the past 12 months, compared with -30.59% for NKTR (price return, excluding dividends). Past performance does not predict future results.
Are Nektar Therapeutics and Omeros in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.